Pediatric Vaccines Market Size To Reach $49.46 Billion By 2030

Pediatric Vaccines Market Growth & Trends

The global pediatric vaccines market size is expected to reach USD 49.46 billion by 2030, registering a CAGR of 4.1%, according to a new report by Grand View Research, Inc. Advancements in development of vaccines and new product launches are some of the major drivers of the market. 

Increase in investments by companies to capture a larger market share is anticipated to propel growth. Some of the factors attributed to increase in investment are high growth prospects in the emerging market, immunization schedule mandated by doctors for children, and awareness programs led by UNICEF, WHO, and other healthcare organizations. Furthermore, increase in number of government initiatives for raising awareness about immunization is expected to boost the market for pediatric vaccines.

Advancements in development of novel adjuvants and therapeutic vaccines are expected to drive growth during the forecast period. Ongoing research in novel molecules targeted at specific mechanisms of action in the body is aimed at providing immunity against fatal diseases such as cancer and Zika virus disease. For instance, in June 2016, Inovio Pharmaceuticals, Inc. announced the initiation of phase I clinical trial for their Zika DNA vaccine named GLS-5700.

 Request a free sample copy or view report summary: Pediatric Vaccines Market Report

Pediatric Vaccines Market Report Highlights

• By type, monovalent emerged as the largest segment due to factors such as high usage and increase in initiatives for R&D activities supported by various governments.

• Conjugate vaccines formed the dominant technology segment in terms of revenue in 2023. Higher adoption of these vaccines and increase in prevalence of infectious diseases contribute to its lead in the market for pediatric vaccines.

• By application, the measles, mumps, and rubella (MMR) segment is projected to grow at the fastest CAGR of 6.1% over the forecast period. This is attributable to the fact that there are still cases of measles, mumps, and rubella which are characteristics of children who have not been vaccinated in areas with poor coverage.

• North America held the largest revenue share in 2023. Its dominance in the market for pediatric vaccines is owing to factors such as local presence of major players in the industry and extensive R&D activities.

• The Asia Pacific region is anticipated to witness lucrative growth over the next decade due to increase in prevalence of infectious diseases and a large target population.

Pediatric Vaccines Market Segmentation

Grand View Research has segmented the global pediatric vaccines market report based on type, technology, application, and region:

Pediatric Vaccines Type Outlook (Revenue, USD Million, 2018 - 2030)

• Monovalent

• Multivalent

Pediatric Vaccines Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Live Attenuated Vaccines

• Inactivated Vaccines

• Subunit Vaccines

• Toxoid Vaccines

• Conjugate Vaccines

• Others

Pediatric Vaccines Application Outlook (Revenue, USD Million, 2018 - 2030)

• Infectious Disease

• Cancer

• Allergy

• Pneumococcal Diseases

• Influenza

• Measles, Mumps, and Rubella (MMR)

• Other Application

Pediatric Vaccines Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Pediatric Vaccines Market

• AstraZeneca

• Sanofi 

• GSK plc

• Pfizer, Inc.

• Zydus Group

• Indian Immunologicals Ltd.

• Serum Institute of India Pvt. Ltd.

• Panacea Biotec

• SINOVAC 

• BIO-MED